Biomet Announces Retirement of President and Chief Executive Officer, Dane A. Miller, Ph.D.; Daniel P. Hann, 17-Year Company Ve

Biomet, Inc. (NASDAQ:BMET) The Board of Directors of
Biomet, Inc. announced today that Dane A. Miller, Ph.D., the Company's
President and Chief Executive Officer and a co-founder, has informed
the Board of his decision to retire and has resigned. He will remain a
Director and serve as a consultant. The Board has appointed Senior
Vice President Daniel P. Hann, the Company's General Counsel and a
member of the Board, to be President and Chief Executive Officer on an
interim basis.
   Scott Harrison, M.D., Lead Director, stated, "Biomet is a true
American success story, and Dr. Miller's extraordinary vision, talent
and leadership over the course of nearly three decades has been
central to its progress and development. He and his co-founders built
this Company into a worldwide leader in the design and manufacture of
reconstructive products with revenues of nearly $2 billion in the
fiscal year ended May 31, 2005, strong values and organizational
standards. What Dr. Miller and his team have achieved is truly
remarkable."
   Niles L. Noblitt, Chairman of the Board, added, "The Board shares
my confidence in the selection of Mr. Hann, a talented and
results-oriented executive with more than 17 years at Biomet, to lead
the Company during this period. He knows the Company intimately,
shares our commitment to building shareholder value, and is well
positioned to move the Company forward," concluded Mr. Noblitt.
   "The Biomet team has built a great company through its passion for
engineering excellence and innovation," said Mr. Hann. Mr. Hann
continued, "Biomet will remain true to its heritage and I believe we
are well positioned to capitalize on the momentum of our successful
exhibition at the recent American Academy of Orthopaedic Surgeons'
Annual Meeting, at which the Company introduced over 100 new
products."
   Dr. Miller stated, "I believe in Biomet and its team members, and
their ability to continue to deliver quality products and enhance
shareholder value. As I begin a new stage in my life, I will always be
grateful to have worked with the great people at Biomet and to have
played a role in its growth and success."
   Dr. Miller, 60, was one of the four founders of Biomet and has
been President, Chief Executive Officer and a Director of the Company
since its formation in 1977.
   Mr. Hann, 50, joined Biomet in 1989 as an officer and Director. He
is a member of the NASDAQ Listing and Hearing Review Council of the
NASDAQ Stock Market, Inc. He received his B.S. from California State
University, Fullerton, his M.S. from the University of Illinois, and
his J.D. from Indiana University.
   In conjunction with today's announcement, you are invited to
listen to a conference call that will be broadcast live over the
internet today at 1:00 p.m. Eastern Time.
   The live webcast of Biomet's conference call will be accessible
through Biomet's website at www.biomet.com (Investor Section) and at
www.streetevents.com. The webcast will be archived on both websites
for future on-demand replay.
   Individuals wishing to listen to the call via phone may dial
800-475-3716. The confirmation number for the call is 9274638.
   Biomet, Inc. and its subsidiaries design, manufacture and market
products used primarily by musculoskeletal medical specialists in both
surgical and non-surgical therapy. The Company's product portfolio
encompasses reconstructive products, including orthopedic joint
replacement devices, bone cements and accessories, and dental
reconstructive implants; fixation products, including electrical bone
growth stimulators, internal and external orthopedic fixation devices,
craniomaxillofacial implants and bone substitute materials; spinal
products, including spinal stimulation devices, spinal hardware and
orthobiologics; and other products, such as arthroscopy products and
softgoods and bracing products. Headquartered in Warsaw, Indiana,
Biomet and its subsidiaries currently distribute products in more than
100 countries.
   For further information contact Greg W. Sasso, Vice President,
Corporate Development and Communications at [phone] or Barbara
Goslee, Manager, Corporate Communications at [phone].
   This press release contains certain statements that are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, as amended. Although the Company believes that the
assumptions, on which the forward-looking statements contained herein
are based, are reasonable, any of those assumptions could prove to be
inaccurate given the inherent uncertainties as to the occurrence or
non-occurrence of future events. There can be no assurance that the
forward-looking statements contained in this press release will prove
to be accurate. Some of the factors that could cause actual results to
differ from those contained in forward-looking statements made in this
press release include the success of the Company's principal product
lines and reorganization efforts with respect to its EBI operations,
the Company's ability to develop and market new products and
technologies in a timely manner, government regulation, currency
exchange rate fluctuations, reimbursements from third party payors,
litigation, revenue and earnings estimates, and other risk factors as
set forth from time to time in the Company's filings with the SEC. The
inclusion of a forward-looking statement herein should not be regarded
as a representation by the Company that the Company's objectives will
be achieved. The Company undertakes no obligation to publicly update
forward-looking statements, whether as a result of new information,
future events or otherwise.
   All of Biomet's financial information may be obtained on our
website at www.biomet.com or you may contact us by e-mail at
[e-mail].